Alpha Cognition (ACOG) Fireside Chat summary
Event summary combining transcript, slides, and related documents.
Fireside Chat summary
3 Dec, 2025Introduction and agenda
Fireside chat format with pre-set questions and open Q&A for investors, focusing on commercial adoption and clinical development.
Current industry trends
Long-term care market for Alzheimer's is valued at $2.2 billion, with 15,000 nursing homes in the US, 5,000 specializing in Alzheimer's.
Most patients are switched from generics like Aricept due to side effects and loss of efficacy, with ZUNVEYL positioned as a better-tolerated alternative.
Challenges and overcoming obstacles
Inventory build remains choppy due to rapid growth and distributor adjustments, expected to normalize in two quarters.
Payer coverage is expanding gradually, with critical mass expected after three PBM contracts by 2026.
Adherence in nursing homes is high, but tolerability and polypharmacy remain key challenges.
Latest events from Alpha Cognition
- Shareholders will vote on board composition, auditor appointment, and executive compensation.ACOG
Proxy filing30 Apr 2026 - Shareholders to vote on board size, director elections, and auditor appointment at June 2026 AGM.ACOG
Proxy filing30 Apr 2026 - ZUNVEYL's rapid growth and LTC focus drive strong revenue and market expansion.ACOG
Corporate presentation30 Mar 2026 - 2025 revenue hit $10.2M with rapid ZUNVEYL adoption and $66M cash supporting 2027 profitability.ACOG
Q4 202526 Mar 2026 - FDA-approved ZUNVEYL launches in March, targeting LTC Alzheimer's with improved tolerability.ACOG
Investor Update9 Jan 2026 - ZUNVEYL launched in US, $52.8M raised, and strong liquidity supports global expansion.ACOG
Q4 202427 Dec 2025 - Biopharma seeks up to $250M to fund Alzheimer's drug launch and pipeline, with $75M ATM offering.ACOG
Registration Filing16 Dec 2025 - 2.38M shares registered for resale; ZUNVEYL launch and Asia-Pacific deal drive growth.ACOG
Registration Filing16 Dec 2025 - ZUNVEYL's launch and Asia-Pacific licensing drive growth amid ongoing net losses and Nasdaq listing.ACOG
Registration Filing16 Dec 2025